Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Published human evidence includes topical applications over defined periods, diabetic-ulcer wound protocols, and a registered topical acute-wound trial, while there is no FDA-approved injectable GHK-Cu label that establishes a standard dose [2], [3], [7], [8]
Many patients pair it with functional medicine, hormone therapy, or IV therapy as part of a broader plan
Research from the Choi laboratory at Yonsei University established that CXXC5, a negative regulator of Wnt/beta-catenin signalling, is upregulated in miniaturised hair follicles and arrector pili muscles in human balding scalps
\n\n\n\n 7
& Movassat, J
in addition to anti-psychotic medication) group in comparison to the placebo group over a 24-week period, but not positive symptoms [7]
